alexa

GET THE APP

The Point on N-acetylcysteine in Idiopathic Pulmonary Fibrosis Treatment | OMICS International | Abstract
ISSN: 2165-7386

Journal of Palliative Care & Medicine
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

The Point on N-acetylcysteine in Idiopathic Pulmonary Fibrosis Treatment

Rindone E1 and Rosset L2*

1Department of Clinical Biological Sciences, Faculty of Medicine and Surgery, San Luigi Gonzaga, University of Turin, Turin, Italy

2Faculty of Medicine and Surgery, San Luigi Gonzaga, University of Turin, Turin, Italy

*Corresponding Author:
Rosset L
Faculty of Medicine and Surgery
San Luigi Gonzaga, University of Turin
Turin, Italy
Tel: 393386100741
E-mail: [email protected]

Received date: April 21, 2014; Accepted date: October 16, 2014; Published date: October 26, 2014

Citation: Rindone E, Rosset L (2014) The Point on N-acetylcysteine in Idiopathic Pulmonary Fibrosis Treatment. J Palliat Care Med 4:193. doi:10.4172/2165-7386.1000193

Copyright: © 2014 Rindone E, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Idiopathic pulmonary fibrosis (IPF) is still a non-curable disease. The suggested therapy consists of Pirfenidone combined with other drugs like azathioprine, and acetylcysteine. The New England Journal of Medicine published a new study that goes against the common use of N-acetylcysteine (NAC) to treat IPF patient. There are other studies that went in favor of N-acetylcysteine. The present study reviews the entire developments and sums up the reality by affirming that new studies should be done to demonstrate whether the NAC should be administered in combination with Pirfenidone or not, as the last study did not clarify this point.

Keywords

Top